Global Protein Stability 

Syd Biotechnologies offers global protein stability analysis using advanced yeast surface display technology. This platform enables the assessment and engineering of the stability of large protein libraries in a single, high-throughput experiment. 

The process begins with in-silico design of engineered peptide sequences. These genes are synthesised, cloned into the pSYDYD 3.0 yeast display vector (or project-specific vector), and simultaneously expressed on the surface of yeast cells. 

Displayed peptides are then challenged with various destabilising agents—including proteases like trypsin and chymotrypsin, shifts in temperature and pH, as well as denaturants such as urea and guanidinium hydrochloride. High-throughput screening enables the identification of protein variants with significantly enhanced stability. 

This approach supports the development of more stable and functionally robust proteins for a range of applications, including therapeutic antibody development and industrial enzyme optimisation. 

Service Highlights 

• Optimized yeast display vector.  

• High-throughput screening.  

• Eukaryotic environment.  

• Direct analysis on cell surface.  

• Highly applicable in protein engineering.  

• All services under one roof.  

Experiment Steps:

Custom PhIP-Seq Service for Profiling of Autoantibodies 

Syd Biotechnologies offers Custom Phage ImmunoPrecipitation Sequencing (PhIP-Seq) services for comprehensive profiling of autoantibodies present in patient serum, leveraging advanced phage display technology. 

This platform utilises a phage display library constructed from predesigned oligopeptides ranging from 50 to 90 amino acids, cloned into a modified T7 Select vector developed in-house at Syd Biotechnologies. The library is then screened using antibody pools isolated from patients with suspected or confirmed autoimmune disorders. 

Following incubation, the antibody–phage complexes are selectively captured using Protein A/G resin. A two-step PCR process is employed: the first round amplifies and purifies the phage-insert sequences; the second round adds unique index barcodes to differentiate the samples. Sequencing is performed using the Illumina MiSeq platform. 

Post-sequencing, FastQ files are demultiplexed, aligned, and analysed to determine enrichment patterns of patient-specific autoantibodies. PhIP-Seq is a powerful tool for investigating environmental exposures, allergies, emerging autoimmune conditions, and patient responses to immunomodulatory therapies.